Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent

Journal of Immunology

Volumn 160, Issue 11, 1998, Pages 5588-5595

  Martiney, James A ^a,c   Rajan, Alice J ^b   Charles, Peter C ^b   Cerami, Anthony ^c   Ulrich, Peter C ^c   Macphail, Stuart ^d,e   Tracey, Kevin J ^a   Brosnan, Celia F ^b  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Kenneth S Warren Laboratories   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e Fish & Richardson PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYDRAZONE DERIVATIVE; N,N' BIS[3,5 BIS[1 [(AMINOIMINOMETHYL)HYDRAZANO]ETHYL]PHENYL]DECANEDIAMIDE TETRAHYDROCHLORIDE; SEMAPIMOD; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DOSE RESPONSE; DRUG MECHANISM; FEMALE; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; WHITE MATTER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; CYTOKINES; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HYDRAZONES; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; RECURRENCE; RNA, MESSENGER; SPINAL CORD; T-LYMPHOCYTES;

EID: 0032103940     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Swanborg, R. H. 1995. Animal models of human disease: experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol Immunopathol. 77:4.
2. Alvord, E. C., M. W. Kies, and A. J. Suckling. 1984. Experimental allergic encephalomyelitis: a useful model for multiple sclerosis. Prog. Clin. Biol. Res. 146:1.
3. Martin, R., and H. F. McFarland. 1995. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32:121.
4. Selmaj, K. W. 1992. The role of cytokines in inflammatory conditions of the central nervous system. Semin. Neurosci. 4:221.
5. Raine, C. S. 1995. Multiple sclerosis: TNF revisited, with promise. Nat. Med. 1:211.
6. Brosnan, C. F., and C. S. Raine. 1996. Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 6:243.
7. Hartung, H.-P., J. J. Archelos, J. Zielasek, R. Gold, M. Koltzenburg, K.-H. Reiners, and K. V. Toyka. 1995. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 45(Suppl. 6):S22.
8. Selmaj, K. W., and C. S. Raine. 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neural. 23:339.
9. Zimmerman, G. A., S. B. Martin, and K. J. Tracey. 1994. The neuroimmunology of tumor necrosis factor-α. Clin. Immunother. 1:67.
10. Feuerstein, G. Z., T. Liu, and F. C. Barone. 1994. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc. Brain Metab. Rev. 6:341.
11. Renno, T., M. Krakowski, C. Piccirillo, J. Y. Lin, and T. Owens. 1995. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis: regulation by Th1 cytokines. J. Immunol. 154:944.
12. Turner, M., M. London, and M. Feldman. 1987. Human T cells from autoimmune and normal individuals can produce tumor necrosis factor. Eur. J. Immunol. 17:1807.
13. Lieberman, A. P., P. M. Pitha, H. S. Shin, and M. L. Shin. 1989. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl. Acad. Sci. USA 86:6348.
14. Frei, K., C. Seipl, P. Groscurth, C. Schwerdel, and A. Fontana. 1987. Antigen presentation and tumor cytotoxicity by Interferon-γ-treated microglial cells. Eur. J. Immunol. 17:1271.
15. Righi, M., L. Mori, G. De Libero, M. Sironi, A. Biondi, A. Mantovani, S. D. Donini, and P. Ricciardi-Castagnoli. 1989. Monokine production by microglial cell clones. Eur. J. Immunol. 19:1443.
16. Huitinga, I., S. R. Ruuls, S. Jung, N. Van Rooijen, H.-P. Hartung, and C. D. Dijkstra. 1995. Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin. Exp. Immunol. 100:344.
17. Brosnan, C. F., M. B. Bornstein, and B. R. Bloom. 1981. The effects of macrophage depletion on the clinical and pathological expression of experimental allergic encephalomyelitis. J. Immunol. 130:1503.
18. Huitinga, I., N. Van Rooijen, C. J. A. deGroot, B. M. J. Uitdehaag, and C. D. Dijkstra. 1990. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172:1025.
19. Brosnan, C. F., B. Canella, L. Battistini, and C. S. Raine. 1995. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 45(Suppl. 6):S16.
20. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193.
21. Selmaj, K., C. S. Raine, and A. H. Cross. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:694.
22. Baker, D., D. Butler, B. J. Scallon, J. K. O'Neill, J. L. Turk, and M. Feldmann. 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24:2040.
23. Selmaj, K., W. Papierz, A. Glabinski, and T. Kohno. 1995. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol 56:135.
24. Selmaj, K., C. S. Raine, B. Cannella, and C. F. Brosnan. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87:949.
25. Hofman, F. M., D. R. Hinton, and J. E. Merrill. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170:607.
26. Sharief, M. K., and R. Hentges. 1991. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325:467.
27. Benvenuto, R., M. Paroli, C. Buttinelli, A. Franco, V. Barnaba, C. Fieschi, and F. Balsano. 1991. Tumor necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis. Clin. Exp. Immunol. 84:97.
28. Sharief, M. K., and E. J. Thompson. 1992. In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J. Neuroimmunol. 38:27.
29. Cohen, P. S., H. Schmidtmayerova, J. Dennis, L. Dubrovsky, B. Sherry, H. Wang, M. Bukrinsky, and K. Tracey. 1997. The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol. Med. 3:339.
30. Bianchi, M., O. Bloom, T. Raabe, P. S. Cohen, J. Chesney, B. Sherry, H. Schmidtmayerova, T. Calandra, X. N. Zhang, M. Bukrinsky, P. Ulrich, A. Cerami, and K. J. Tracey. 1996. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J. Exp. Med. 183:927.
31. Tracey, K. J. 1998. Suppression of TNF and other proinflammatory cytokines by the tetravalent guanylhydrazone CNI-1493. In Endotoxin and Sepsis: Molecular Mechanisms of Pathogenesis, Host Resistance, and Therapy. John Wiley & Sons, New York. In press.
32. Bianchi, M., P. Ulrich, O. Bloom, M. Meistrell, G. A. Zimmerman, H. Schmidtmayerova, M. Bukrinsky, T. Donnelly, R. Bucala, B. Sherry, K. R. Manogue, A. J. Tortolani, A. Cerami, and K. J. Tracey. 1995. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol. Med. 1:254.
33. Cerami, C., X. Xhang, P. Ulrich, M. Bianchi, K. J. Tracey. and B. J. Berger. 1995. High-performance liquid chromatographic method for guanylhydrazone compounds which prevent acute inflammation and toxic shock syndrome. J. Chromatogr. 675:71.
34. Brosnan, C. F., M. K. Racke, and K. Selmaj. 1997. An investigational approach to disease therapy in multiple sclerosis. In Multiple Sclerosis: Clinical and Pathogenic Basis. C. S. Raine, H. F. McFarland, and W. W. Tourtellote, eds. Chapman and Hall, London, pp. 325-340.
35. Bjork, L., K. J. Tracey, P. C. Ulrich, M. Bianchi, P. S. Cohen, K. Akerlund, T. E. Fehniger, U. Andersson, and J. Andersson. 1997. Targeted suppression of cytokine production in monocytes but not in lymphocytes by a tetravalent guanylhydrazone (CNI-1493). J. Infect. Dis. 176:1303.
36. Cross, A. H., P. T. Manning, M. K. Stern, and T. P. Misko. 1997. Evidence for the production of peroxynitrate in inflammatory CNS demyelination. J. Neuro-immunol. 80:121.
37. Racke, M. K., S. Dhib-Jalbut, B. Canella, P. S. Albert, C. S. Raine, and D. E. McFarlin. 1991. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 146:3012.
38. Cross, A. H., R. M. Keeling, S. Goorha, M. San, C. Rodi, P. S. Wyatt, P. T. Manning, and T. P. Misko. 1996. Inducible nitric oxide synthase gene expression and enzyme activity correlate with disease activity in murine experimental autoimmune encephalomyelitis. J. Neuroimmunol. 71:145.
39. Cross, A. H., T. P. Misko, R. F. Lin, W. F. Hickey, J. L. Trotter, and R. G. Tilton. 1994. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93:2684.
40. Kent, S. J., S. J. Karlik, C. Cannon, D. K. Hines, T. A. Yednock, L. C. Fritz, and H. C. Homer. 1995. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58:1.